Home > Healthcare > Pharmaceuticals > Vaccines > Live Attenuated Vaccines Market

Live Attenuated Vaccines Market Trends

Report ID: GMI8782
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Live Attenuated Vaccines Market Trends

Governments, healthcare organizations, and individuals are increasingly recognizing the importance of vaccination including influenza vaccines in preventing infectious diseases and promoting public health. For instance, in February 2020, governments led the initiatives, with funding from Gavi, and support from partners like the Vaccine Alliance and the Measles & Rubella Initiative (M&RI), which comprises organizations such as WHO and UNICEF.
These efforts aimed to focus on children under five years old particularly susceptible to measles and disease. The campaign aimed to immunize approximately 45 million children across seven developing nations in the six months. Thus, by implementing these comprehensive vaccination campaigns, the market is expected to show significant opportunities.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global live attenuated vaccines market crossed USD 14.5 billion in 2023 and is expected to reach USD 35.6 billion by 2032, due to the increasing incidences of viral and bacterial infections worldwide.

The viral vaccines type segment held a significant share in 2023 and is set to grow at 10.3% CAGR between 2024 – 2032, driven by a higher prevalence of viral diseases globally.

North America live attenuated vaccines industry held a decent market share in 2023 and is anticipated to reach USD 12 billion by 2032, owing to the presence of advanced research facilities.

Boehringer Ingelheim International GmbH, GlaxoSmithKline, plc., Haffkine Biopharmaceutical Corporation Limited, HBI, Merck & Co., Sanofi, Serum Institute of India Ltd., Valneva SE, Zydus Group among others